LivaNova (NASDAQ:LIVN) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of LivaNova (NASDAQ:LIVN) in a report issued on Monday,Benzinga reports. Needham & Company LLC currently has a $64.00 price target on the stock.

LIVN has been the subject of a number of other research reports. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. The Goldman Sachs Group dropped their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Mizuho dropped their price objective on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Finally, Barclays dropped their price objective on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.17.

LivaNova Trading Up 5.5 %

LIVN opened at $41.41 on Monday. The company’s 50 day moving average is $45.88 and its 200-day moving average is $49.01. The company has a market cap of $2.25 billion, a P/E ratio of 98.60 and a beta of 1.10. LivaNova has a 1-year low of $36.85 and a 1-year high of $64.48. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. bought a new position in LivaNova during the 4th quarter worth approximately $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in LivaNova by 25.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock worth $7,107,000 after purchasing an additional 30,718 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of LivaNova by 74.3% in the 4th quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock valued at $5,161,000 after acquiring an additional 47,494 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of LivaNova by 148.5% in the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock valued at $9,936,000 after acquiring an additional 128,200 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of LivaNova by 27.2% in the 4th quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock valued at $20,357,000 after acquiring an additional 93,985 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.